---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-011061"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:02:46.635864+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InfuSystem reports FY2023 record revenue $125.8M, +14%; EPS $0.04; guides FY2024 high-single-digit growth

## Summary
- FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).
- Q4 net revenue $31.8M (+10%); net income $0.1M ($0.00 diluted EPS) vs $0.1M ($0.01) prior year.
- Adjusted EBITDA $22.4M (+8%); operating income $4.1M (+147%); net income $0.9M vs $0.0M prior year.
- FY2024 guidance: high-single-digit revenue growth; Adjusted EBITDA margin in high-teens (above 17.8%).
- Joint venture SI Wound Care (with Sanara MedTech) expected to generate meaningful revenue in 2025.

## SEC filing metadata
- accession: 0001628280-24-011061
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/0001628280-24-011061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/infu-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-011061
- JSON: https://secwatch.observer/filing/0001628280-24-011061.json
- Plain text: https://secwatch.observer/filing/0001628280-24-011061.txt

## Key facts
- Earnings Releases
  InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2023 results: revenue Net revenues totaled $125.8 million. Guidance reaffirmed.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: Net revenues totaled $125.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023 Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - Device Solutions Revenue: $49.2 million, increases of 11% and 20% Adjusted EBITDA (non-GAAP): $22.4 million, an 8%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/0001628280-24-011061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.